The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic
Background: Patients with inflammatory bowel disease (IBD) often require the use of immunosuppressant medications that increase infection risk, leading to concerns over the safe use of IBD medications during the Coronavirus 19 (COVID-19) pandemic. Objectives: To summarize available evidence on the s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Current Research in Pharmacology and Drug Discovery |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257122000219 |
| _version_ | 1811184509858611200 |
|---|---|
| author | Chethana Kamath, MD Erica J Brenner, MD, MSCR |
| author_facet | Chethana Kamath, MD Erica J Brenner, MD, MSCR |
| author_sort | Chethana Kamath, MD |
| collection | DOAJ |
| description | Background: Patients with inflammatory bowel disease (IBD) often require the use of immunosuppressant medications that increase infection risk, leading to concerns over the safe use of IBD medications during the Coronavirus 19 (COVID-19) pandemic. Objectives: To summarize available evidence on the safety and appropriate use of IBD medications during the COVID-19 pandemic, particularly in regard to risk of severe COVID-19 outcomes such as hospitalization, respiratory failure, or death for patients on IBD therapeutics. Conclusions: The majority of IBD medications are safe to continue during the COVID-19 pandemic, with a few notable exceptions. Patients with IBD who do not have COVID-19 should continue their prescribed IBD therapies, although steroids are associated with severe COVID-19 outcomes and should be weaned when possible. Corticosteroids should be tapered and discontinued when possible in patients with IBD who test positive for COVID-19 as well. Patients with IBD who test positive for COVID-19 should hold biologics, thiopurines, methotrexate, and tofacitinib for at least 2 weeks, and those who have symptoms should not restart these medications until symptom resolution. During the COVID-19 pandemic, all patients with IBD should continue to follow public health guidance including social distancing, masking, and COVID-19 vaccination recommendations. |
| first_indexed | 2024-04-11T13:13:22Z |
| format | Article |
| id | doaj.art-23d13205206c484ab3be8ee407f6f64c |
| institution | Directory Open Access Journal |
| issn | 2590-2571 |
| language | English |
| last_indexed | 2024-04-11T13:13:22Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Pharmacology and Drug Discovery |
| spelling | doaj.art-23d13205206c484ab3be8ee407f6f64c2022-12-22T04:22:28ZengElsevierCurrent Research in Pharmacology and Drug Discovery2590-25712022-01-013100101The safe use of inflammatory bowel disease therapies during the COVID-19 pandemicChethana Kamath, MD0Erica J Brenner, MD, MSCR1Corresponding author. Pediatric Education Office CB 7593, Chapel Hill, 27599, USA.; Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADivision of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USABackground: Patients with inflammatory bowel disease (IBD) often require the use of immunosuppressant medications that increase infection risk, leading to concerns over the safe use of IBD medications during the Coronavirus 19 (COVID-19) pandemic. Objectives: To summarize available evidence on the safety and appropriate use of IBD medications during the COVID-19 pandemic, particularly in regard to risk of severe COVID-19 outcomes such as hospitalization, respiratory failure, or death for patients on IBD therapeutics. Conclusions: The majority of IBD medications are safe to continue during the COVID-19 pandemic, with a few notable exceptions. Patients with IBD who do not have COVID-19 should continue their prescribed IBD therapies, although steroids are associated with severe COVID-19 outcomes and should be weaned when possible. Corticosteroids should be tapered and discontinued when possible in patients with IBD who test positive for COVID-19 as well. Patients with IBD who test positive for COVID-19 should hold biologics, thiopurines, methotrexate, and tofacitinib for at least 2 weeks, and those who have symptoms should not restart these medications until symptom resolution. During the COVID-19 pandemic, all patients with IBD should continue to follow public health guidance including social distancing, masking, and COVID-19 vaccination recommendations.http://www.sciencedirect.com/science/article/pii/S2590257122000219 |
| spellingShingle | Chethana Kamath, MD Erica J Brenner, MD, MSCR The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic Current Research in Pharmacology and Drug Discovery |
| title | The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic |
| title_full | The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic |
| title_fullStr | The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic |
| title_full_unstemmed | The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic |
| title_short | The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic |
| title_sort | safe use of inflammatory bowel disease therapies during the covid 19 pandemic |
| url | http://www.sciencedirect.com/science/article/pii/S2590257122000219 |
| work_keys_str_mv | AT chethanakamathmd thesafeuseofinflammatoryboweldiseasetherapiesduringthecovid19pandemic AT ericajbrennermdmscr thesafeuseofinflammatoryboweldiseasetherapiesduringthecovid19pandemic AT chethanakamathmd safeuseofinflammatoryboweldiseasetherapiesduringthecovid19pandemic AT ericajbrennermdmscr safeuseofinflammatoryboweldiseasetherapiesduringthecovid19pandemic |